Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colorectal Neoplasms × olaparib × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 15 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Breast Neoplasms 4 Fallopian Tube Neoplasms 3 Neoplasm Metastasis 2 Metastatic Castration-resistant Prostate Cancer 2 Endometrial Neoplasms 2 Carcinoma 2 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasms 1 Hematologic Neoplasms 1 HER2-ve Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1

Interventions

Fluorouracil 104 Leucovorin 97 Oxaliplatin 74 Bevacizumab 68 Irinotecan 57 Capecitabine 53 Cetuximab 34 Folfox protocol 27 Panitumumab 15 regorafenib 13 Drug Therapy 13 trifluridine tipiracil drug combination 12 Chemotherapy, Adjuvant 11 IFL protocol 9 Radiotherapy 8 Neoadjuvant Therapy 7 Floxuridine 7 Aspirin 6 pembrolizumab 5 XELOX 5 Levoleucovorin 5 Laparoscopy 5 dehydroftorafur 4 atezolizumab 4 Trifluridine 4 Octreotide 4 Mitomycin 4 Magnetic Resonance Spectroscopy 4 Celecoxib 4 xaliproden 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04456699 2024-10-29

LYNK-003

Merck Sharp & Dohme LLC

Phase 3 Completed

335 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡